The nucleoside inhibitor has advantages over Gilead's remdesivir but has yet to be tested in humans

Qiagen vows to ramp up production of kits as scientists turn to social media to plea for donations

Companies are making their machines and expertise available to hospitals in need of parts

Medicinal chemists focus on the main protease of SARS-CoV-2 to develop antiviral treatments for COVID-19

Gilead Sciences' antiviral is in multiple late-stage trials to treat coronavirus infections. Don't expect a home run, say infectious disease experts

The National Institutes of Health receives the vast majority of the support

Bacteria with antimicrobial-resistance genes pass from livestock to farm interns

Chemically distinct regions of alloys can help create strong yet flexible nanostructured metals

Researchers aim to supply evidence to save lives, persevering through lack of recognition and funding

Researchers study and model corrosion in the materials proposed for locking away the hazardous waste

Technology could lessen the environmental impact of 3-D printed buildings by adapting locally harvested soils

Activists say broad lack of enforcement threatens safety

Awardees will attend a weeklong program in Columbus in August

Lingering logistic problems and a sputtering economy mean hard times for companies

Resources are freely available through April 17

US EPA finds unreasonable risks for 6 current uses, including chlor-alkali diaphragms

With a diagnostic backlog hampering disease control efforts, scientists are turning to CRISPR and other technologies to bridge the gap

C&EN advice columnist offers 4 tips on adapting to times of uncertainty

System combines compounds in unfamiliar ways

New design based on interconnected plates pushes theoretical strength limits

Using lasers to directly create graphene on Kevlar makes it easy to integrate electronics on textiles

Auto manufacturing is the first sector to halt demand for chemicals

These biomolecules could hold clues to why the virus is so infectious and to how to stop it

Drugmakers want to keep trials going but acknowledge that medical resources are strained

Lingering logistic problems and a sputtering economy mean hard times for companies

Editors in Europe and the US plan to work with authors whose lives and labs have been disrupted by the novel coronavirus

Long-sought phosphatetrahedrane could lead to new organophosphorus compounds

Chemours plans to appeal the decision to Delaware's Supreme Court

Fingers are being pointed in the Netherlands and the UK over reagent capacity constraints

Open-access collection contains nearly 50,000 chemical compounds from the CAS Registry

Kelvin Droegemeier takes over the agency until Congress confirms nominee